Fri 06/12/2020 14:41 PM
Takeaways
- One source familiar with the situation said conversations with senior people working for AstraZeneca indicate there is little substance to the report and no active deal.
- Megamergers are still a regular point of discussion among C-level execs and advisors, but they acknowledged the risk of engaging in serious megamerger talks prior to the U.S. elections in November given it takes months, if not years, for a deal to close, sources said.
- The biggest “take-home” from...
This article is an example of the content you may receive if you subscribe to a product of Reorg Research, Inc. or one of its affiliates (collectively, “Reorg”). The information contained herein should not be construed as legal, investment, accounting or other professional services advice on any subject. Reorg, its affiliates, officers, directors, partners and employees expressly disclaim all liability in respect to actions taken or not taken based on any or all the contents of this publication. Copyright © 2024 Reorg Research, Inc. All rights reserved.